

HEMATOPOIESIS AND STEM CELLS

Ikaros limits basophil development by suppressing C/EBP- α expressionKavitha N. Rao,¹ Craig Smuda,¹ Gregory D. Gregory,¹ Booki Min,² and Melissa A. Brown¹¹Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL; and ²Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

Key Points

- $Ik^{-/-}$ mice overproduce basophils and their precursors in the absence of extrinsic inflammatory signals.
- Ikaros restrains development of basophils by regulating histone modifications at lineage-specifying genes, including *Cebpa* and *Hes1*.

The Ikaros gene (*Ikzf1*) encodes a family of zinc-finger transcription factors implicated in hematopoietic cell differentiation. Here we show that Ikaros suppresses the development of basophils, which are proinflammatory cells of the myeloid lineage. In the absence of extrinsic basophil-inducing signals, $Ik^{-/-}$ ($Ik^{-/-}$) mice exhibit increases in basophil numbers in blood and bone marrow and in their direct precursors in bone marrow and the spleen, as well as decreased numbers of intestinal mast cells. In vitro culture of $Ik^{-/-}$ bone marrow under mast cell differentiation conditions also results in predominance of basophils. Basophil expansion is associated with an increase in basophil progenitors, increased expression of *Cebpa* and decreased expression of mast cell-specifying genes *Hes1* and microphthalmia-associated transcription factor (*Mitf*). Ikaros directly associates with regulatory sites within *Cebpa* and *Hes1* and regulates the acquisition of permissive H3K4 tri-methylation marks at the *Cebpa* locus and reduces H3K4 tri-methylation at the *Hes1* promoter. Ikaros blockade in cultured cells or transfer

of $Ik^{-/-}$ bone marrow into irradiated $Ik^{+/+}$ recipients also results in increased basophils confirming a cell-intrinsic effect of Ikaros on basophil development. We conclude that Ikaros is a suppressor of basophil differentiation under steady-state conditions and that it acts by regulating permissive chromatin modifications of *Cebpa*. (*Blood*. 2013;122(15):2572-2581)

Introduction

Mast cells and basophils are related proinflammatory myeloid cells.¹⁻⁴ Both express the $\alpha\beta\gamma_2$ form of the high-affinity immunoglobulin E (IgE) receptor Fc ϵ R1 and, with crosslinking, release a similar spectrum of mediators that contribute to allergic responses and anti-parasite immunity. Although basophils were once considered circulating equivalents of tissue mast cells, it is now appreciated that these cell types exert unique roles in health and disease.^{3,5-7}

In contrast to long-lived tissue-resident mast cells, basophils have a short lifespan, expanding in response to specialized inflammatory cues including interleukin-3 (IL-3) and thymic stromal lymphopoietin.^{8,9} As with mast cells, basophils participate in IgE-mediated allergic inflammation, but exert more profound effects on chronic- and late-phase inflammation¹⁰ and contribute to IgG-dependent systemic anaphylaxis.¹¹ Basophils produce high levels of IL-4 and may present antigen.^{12,13}

Mast cells and basophils can be derived from the multipotent, lineage-restricted granulocyte-monocyte progenitor (GMP).^{14,15} A bipotent basophil mast cell precursor (BMCP), likely derived from the GMP, has also been identified in the spleen,¹ demonstrating that the pathways regulating the differentiation of these cells are interconnected. However, a mast cell-specific developmental pathway arising from earlier myeloid precursors has also been identified.^{16,17}

Microphthalmia-associated transcription factor (MITF), GATA-1, 2 and 3, PU.1, Hes1, and STAT5a/b are among the transcription factors expressed early in developing mast cells, acting in concert to

promote differentiation.¹⁸⁻²⁰ Basophils also express STAT5a/b, GATA-1, and GATA-2, but CCAAT/enhancer binding protein (C/EBP- α) is uniquely important in the development of this lineage. Although widely expressed in the myeloid lineage, the timing of C/EBP- α expression is critical to its function. Notably, enforced overexpression of C/EBP- α in BMCPs results in exclusive differentiation into basophils, whereas conditional deletion of C/EBP- α in these same cells promotes mast cell differentiation,¹ suggesting that C/EBP- α is an essential “switch factor” for basophil lineage choice.

The fate of a multipotent precursor cell results in part from chromatin alterations allowing activation of select subsets of lineage-specific genes and silencing of others. Ikaros, a DNA-binding factor, is well-suited to mediate such alternative fate decisions.²¹ Ikaros comprises a family of DNA-binding and nonbinding isoforms generated by alternative splicing (as reviewed in Georgopoulos²² and in John and Ward²³). Ikaros can associate with activating or suppressive chromatin-remodeling complexes, providing the potential to exert both positive and negative effects on transcription. $Ik^{-/-}$ ($Ik^{-/-}$) mice, which contain a targeted disruption of *Ikzf1*, lack B cells, natural killer cells, and fetal T cells, although T cells populate the periphery after birth.²⁴⁻²⁷ Ikaros also affects dendritic cells, and erythroid and neutrophil development.²⁸⁻³⁰

We previously demonstrated that Ikaros is expressed in bone marrow-derived mast cells, where it regulates the expression of a subset of mast cell genes, including *Il4*.³¹ Here, we initially examined

Submitted April 11, 2013; accepted August 20, 2013. Prepublished online as *Blood* First Edition paper, August 29, 2013; DOI 10.1182/blood-2013-04-494625.


K.N.R. and C.S. contributed equally to this work.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

© 2013 by The American Society of Hematology

Figure 1. $I\kappa^{-/-}$ mice exhibit reduced intestinal mast cell numbers. (A) Mast cells (arrows) were identified in $I\kappa^{-/-}$ mice and their wild-type littermates by toluidine blue staining of sections from ear skin and intestine (original magnification $\times 40$; Zeiss Primo Star with ImagingSource digital camera attachment). (B) Quantification of mast cell numbers in skin and intestine tissue samples. Each data point represents the average number of mast cells observed in an individual mouse counting 4 sections and 5 fields/section. (C) Numbers of MCps in $I\kappa^{+/+}$ and $I\kappa^{-/-}$ mice were assessed by limiting dilution analysis of intestinal mononuclear cells (MNC) in medium containing IL-3 and SCF. Data represents mean MCps from 4 individual mice/group \pm standard error of the mean and are representative of 2 independent experiments. * $P < .05$; ** $P < .01$.



the effect of Ikaros on mast cell development. Mast cells and mast cell precursor (MCp) are reduced in the gut, but $I\kappa^{-/-}$ mice have normal numbers of mast cells in other tissues, indicating that Ikaros is not essential for mast cell development. Surprisingly, basophil numbers are strikingly increased, as are their direct progenitors (basophil precursor [BaP] and BMCP) in bone marrow and the spleen, respectively.

This unsolicited basophil expansion is associated with an increase in *Cebpa* expression and a decreased expression of the mast cell-specifying genes *Hes1* and *Mitf*, as well as *Stat5*, *Gata1*, and *Gata2*, both in vivo and in vitro. Although the absence of Ikaros prompts basophil expansion, wild-type basophils and their precursors do not downregulate *I κ zf1* messenger RNA. Ikaros associates with regulatory sites within the *Cebpa* and *Hes1* loci, and its absence results in the acquisition of permissive marks at the *Cebpa* locus and reduced marks at the *Hes1* promoter. Thus, Ikaros is a suppressor of basophil differentiation under steady-state conditions, acting in part through epigenetic control of *Cebpa* and *Hes1*.

Methods

Mice

The (C57BL/6:SV129) $I\kappa^{-/-}$ mice²⁷ and $I\kappa^{+/+}$ littermates were bred and housed in the specific pathogen-free animal care facilities of Northwestern University. Genotyping was performed by tandem polymerase chain reaction to detect the presence of $I\kappa^{-}$ neo cassette or the intact $I\kappa^{+}$ exon 7 using Terra reagent (Clontech, Mountain View, CA). The (WB \times C57BL/6) *F1-K κ* ^{W/W^v} mice and *K κ* ^{+/+} littermates were purchased from Jackson Laboratories. These studies were approved by the Northwestern University Feinberg School of Medicine Institutional Animal Care and Use committee.

Antibodies and primers

Specific antibodies and primers used in these experiments are listed in supplemental Data (available on the *Blood* Web site).

Cell culture

Bone marrow was harvested from the femurs of 3- to 5-week-old mice and cultured with 5 ng/mL recombinant murine IL-3 (Invitrogen, Carlsbad, CA) alone or with 12.5 ng/mL recombinant murine stem cell factor (SCF) (Invitrogen) in complete RPMI 1640/15% fetal calf serum (Corning Cellgro, Manassas, VA).

Cytometry and cell sorting

Single cell suspensions were prepared from spleens and livers by mechanical dispersion through 70 μ m filters (BD Biosciences, San Jose, CA), and the bone marrow was needle-aspirated. Erythrocytes were lysed with ammonium-chloride-potassium buffer. Cells were blocked with anti-CD16/32 for 10 minutes; in some experiments, fluorescent anti-CD16/32 was substituted. Cells were incubated for 30 to 90 minutes with antibody, washed twice, and analyzed or sorted immediately. For precursor analysis experiments, viability was assessed with SYTOX Blue (Invitrogen). Flow cytometry was performed using a FACS Canto II or LSR II (BD Biosciences). Sorting was performed by core facility staff on a FACS Aria III (BD Biosciences); cells were sorted directly into RNA lysis buffer. FlowJo 9 (TreeStar, Ashland, OR) was used for analysis. "Lineage" is a mixture of anti-CD3, CD4, CD8, CD19, CD45R, Ter119, and Gr-1 antibodies. Absolute cell numbers were determined with TruCount tubes (BD Biosciences) or direct counting.

Mast cell degranulation assay

Degranulation was assessed by β -hexosaminidase release.³² Briefly, bone marrow-derived mast cells were sensitized with 0.5 μ g/mL anti-dinitrophenol (DNP) IgE (Sigma-Aldrich, St. Louis, MO) for 3 hours in RPMI 1640 with IL-3 and SCF. Cells were stimulated with DNP-human serum albumin (Sigma-Aldrich) for 30 minutes in Tyrode's buffer before supernatant collection and lysis of the cell pellet with 0.5% Triton X-100. β -Hexosaminidase activity was measured in the supernatant and in the lysed pellet by incubation with poly-*N*-acetylglucosamine (Sigma-Aldrich) at 405 nm absorbance.

Analysis of mast cell phenotype

Bone marrow mast cells were sensitized as previously described in this article and cross-linked by the addition of DNP-human serum albumin. Surface markers were assessed 10 to 12 hours later by flow cytometry. Supernatant cytokine release was measured by LiquiChip multiplex immunoassays (Qiagen, Valencia, CA).

Limiting dilution MCp assay

The frequency of MCps was assessed as previously described.³³ Briefly, small intestines were removed from mice and digested with 10 U collagenase type IV (Worthington Biochemical Corp., Lakewood, NJ) in 25 mL RPMI 1640 and agitated at 37°C for 20 minutes. Cells were separated on a Percoll gradient (47% to 67%) and interphase mononuclear cells were isolated. Mononuclear cells were serially diluted in RPMI 1640 with IL-3 and SCF from 10⁵ cells/well in 96-well plates. Then 10⁵ irradiated splenocytes (3000 rad) were added to each well to 100 μ L final volume. Mast cell colonies were identified by toluidine blue staining after 10 to 15 days of culture.




Figure 2. c-kit⁺ FcεRI⁺ cells derived from $Ik^{-/-}$ bone marrow cultured under mast cell differentiation conditions exhibit developmental abnormalities. $Ik^{+/+}$ and $Ik^{-/-}$ bone marrow was cultured in IL-3 and SCF for 6 weeks. (A) Analysis of c-kit and FcεRI expression by flow cytometry. (B) $Ik^{+/+}$ and $Ik^{-/-}$ cultures stained with Wright-Giemsa (original magnification $\times 100$). (C) β -hexosaminidase release was determined 30 minutes after FcεRI crosslinking of pre-loaded anti-DNP-IgE and indicated concentrations of DNP-human serum albumin. The percentage of β -hexosaminidase release was calculated as release (%) = supernatant/(supernatant + cell lysate) $\times 100$. Data represents mean of triplicate experiments \pm standard error of the mean. *** $P < .001$ in 10 ng/mL DNP-human serum albumin-treated cultures. (D) Cytokine release at 16 hours postactivation with anti-DNP-IgE and DNP (10 ng/mL) determined by enzyme-linked immunosorbent assay. Data represents mean of replicates from 3 independent cultures \pm standard error of the mean. (E) Basal expression of cell-surface adhesion and activation molecules after 6 weeks in culture. (F) Quantitative reverse transcription PCR analysis of mast cell and basophil lineage-specifying genes in $Ik^{+/+}$ and $Ik^{-/-}$ cultures. Data are expressed as the mean of 3 separate quantitative RT-PCR analyses \pm standard deviation using RNA isolated from same bone marrow culture. * $P < .05$. Results in panels A-E are representative of 3 independent experiments, and results in panel F are representative of 2 independent experiments.

Quantitative RT-PCR

Total RNA was isolated using an RNeasy kit (Promega, Madison, WI) and Superscript III reverse transcriptase (Invitrogen). Reactions consisted of 0.5 μ L complementary DNA or genomic DNA, PerfecTA SYBR Green SuperMix (Quanta BioSciences, Gaithersburg, MD) and 300 nM each of forward and reverse primers. Complementary DNA was quantified using an iCycler iQ5 (Bio-Rad, Hercules, CA). Relative template levels were calculated using the $2^{-\Delta Ct}$ method, with *Hprt1* as reference gene.

Retroviral transduction

To generate retrovirus, Phoenix-Eco packaging cells were transfected using lipofectamine (Invitrogen) with murine stem cell virus plasmids (pMSCV) plasmids.³⁴ pMSCV-Ik7-IRES-H-2K^k or pMSCV-IRES-H2K^k supernatants were adsorbed onto plates pre-coated with 20 μ g/mL Retronectin (Clontech) for 3 hours. After washing the plates, bone marrow cells prestimulated for 12 hours, and IL-3 and SCF were added. Cells were cultured for 2 additional weeks in media with IL-3 alone. Infected cells were purified using anti-H-2K^k MACS beads (Miltenyi Biotec, Auburn, CA) for RNA preparation or stained with anti-H-2K^k antibody for cytometry.

IL-3 complex induction and isolation of basophils

Mouse basophils were isolated ex vivo, as previously described.³⁵ In brief, mice were subcutaneously implanted with a mini-osmotic pump (Alzet,

Cupertino, CA) containing 5 μ g IL-3 (Peprotech, Rocky Hill, NJ). FcεRI⁺ CD49b⁺ basophils were isolated from bone marrow and liver cells by using a fluorescence-activated cell sorter. Purity after sorting was $>99\%$.

ChIP assays

Histone modification and Ikaros-binding assays were performed with 4×10^6 bone marrow-derived mast cells using chromatin immunoprecipitation (ChIP) assay kits (EMD Millipore, Billerica, MA). For Ikaros ChIP, negative control primers amplify a region distant from consensus Ikaros-binding sites. For histone 3, lysine 4 trimethylation (H3K4me3) ChIP, an isotype control was used.


Bone marrow chimeras

Male WBB6-*Ki*^{W/W^v} recipient mice were lethally irradiated (900 cGy) 1 day prior to intravenous injection of 10^7 wild-type or $Ik^{-/-}$ bone marrow cells. Mice were euthanized either 2 or 4 weeks later for analysis.

Statistics

Except where noted, statistical comparisons were performed using Student unpaired *t* test. Analyses were performed using Prism 6 (GraphPad Software, San Diego, CA).

Figure 3. Basophil-like c-kit^{hi} FcεRI⁺ cells predominate in Ik^{-/-} IL-3 bone marrow cultures. Bone marrow cells from Ik^{+/+} and Ik^{-/-} mice were cultured in IL-3 (5 ng/mL). (A) The c-kit and FcεRI expression assessed at day 19 of culture. (B) Ratio of percentage of mast cells (c-kit^{hi} FcεRI⁺) to basophils (c-kit^{lo} FcεRI⁺) over time in wild-type and Ik^{-/-} cultures. Results are representative of 8 experiments with independent bone marrow cultures. (C) c-kit and FcεRI expression in cultured bone marrow cells at day 28 of culture. (D) Ik^{+/+} c-kit^{hi} FcεRI⁺ cells (top panel), Ik^{-/-} c-kit⁺ FcεRI⁺ (middle panel), and Ik^{-/-} c-kit^{hi} FcεRI⁺ cells (bottom panel) were analyzed for expression of markers that define the basophil phenotype (2B4⁺ CD11b⁺ Thy1.2⁺ IL3Rα^{hi}, solid lines). Shaded peaks: isotype control antibody. (A-D) Representative of 3 experiments with independent bone marrow cultures. (E) Wright-Giemsa staining of fluorescence-activated cell sorted Ik^{-/-} c-kit^{hi} FcεRI⁺ cells (original magnification ×100), representative of 2 experiments. (F) Quantitative RT-PCR analysis of mast cell and basophil lineage-specifying genes in whole Ik^{+/+} and Ik^{-/-} cultures. Data are the mean of 3 separate quantitative RT-PCR analyses ± standard deviation using RNA isolated from the same bone marrow culture. **P* < .05. (G) Kinetics of lineage-determining gene expression assessed by quantitative RT-PCR analysis in IL-3 only Ik^{+/+} and Ik^{-/-} cultures. Data represents mean of quadruplicates at each time point ± standard error of the mean, representative of 2 experiments.



Results

Ik^{-/-} mice lack intestinal mast cells

Ikaros is expressed in bone marrow-derived mast cells and regulates *Il4* expression,³¹ prompting us to ask if Ikaros impacts mast cell development in vivo. Mast cell distribution was assessed in Ik^{-/-} mice by toluidine blue staining of tissues. Although mast cell numbers in the skin (Figure 1A), spleen, heart, and dura mater (data not shown) are normal, Ik^{-/-} mice have significantly reduced numbers of intestinal mast cells (Figure 1B). Reduced numbers of MCs are also observed in the small intestines of Ik^{-/-} mice (Figure 1C).

Ik^{-/-} bone marrow cells cultured under mast cell differentiation conditions (IL-3 and SCF) exhibit developmental and functional alterations

Next, we asked if Ikaros deficiency affects mast cell differentiation or function in vitro. Culture of wild-type bone marrow cells in IL-3 and SCF generates a virtually pure population of c-kit^{hi} FcεRI⁺

mast cells within 4 to 8 weeks.³⁶ In both Ik^{+/+} and Ik^{-/-} cultures, c-kit^{hi} FcεRI⁺ cells predominate after 6 weeks (Figure 2A). However, subtle differences in cell morphology were observed after staining with Wright-Giemsa (Figure 2B). Ik^{-/-} cells appear less densely granulated with a smoother cell surface than wild-type mast cells.

Differentiated Ik^{-/-} cells exhibit a hyper-responsive phenotype with FcεRI crosslinking, releasing more granule-associated β-hexosaminidase (Figure 2C) and proinflammatory IL-6 and tumor necrosis factor (Figure 2D). There are marked differences in the basal expression of cell surface molecules, including CD49b (integrin α2), CD44, CD54 (intercellular adhesion molecule-1), and, notably, CD49d (integrin α4), required for mast cell gut homing³³ (Figure 2E). We also observed increased basal and activation-dependent increases in expression of the costimulatory molecules 4-1BB, CD153 (CD40L), OX40L, and PD-L2 (supplemental Figure 1).

The gene expression profile of Ik^{-/-} cells reflects aberrant mast cell differentiation. Genes associated with mast cell development and function, including *Mitf*, *Gata1*, *Gata2*, *Stat5a*, *Hes1*, *Cpa3* (carboxypeptidase A3), *Cma1* (*Mcpt5*, mouse mast cell protease-5/chymase), and *Tpsb2* (*Mcpt6*, mouse mast cell protease-6/tryptase)^{18-20,37} show reduced expression (Figure 2F). These reductions coincide




Figure 4. $Ik^{-/-}$ mice exhibit increased basophils in the absence of infection. (A) Proportion of c-kit⁺ FcεRI⁺ cells in indicated tissues of naive $Ik^{+/+}$ and $Ik^{-/-}$ mice assessed by flow cytometry. Blood basophils were evaluated for the expression of FcεRI and CD200R3 after gating on c-kit⁺ cells. Numbers denote percentage of basophils. (B) Quantification of basophil (c-kit⁺ FcεRI⁺ CD200R3⁺) and eosinophil (c-kit⁺ Ly6G⁺ Siglec-F⁺) numbers in bone marrow of wild-type and $Ik^{-/-}$ mice by TruCount bead assay. $P < .05$ (C) Cell surface expression of basophil markers in c-kit⁺ FcεRI⁺ cells from $Ik^{-/-}$ bone marrow determined by flow cytometry. (D) Fluorescence-activated cell sorted $Ik^{-/-}$ c-kit⁺ FcεRI⁺ bone marrow cells were subject to quantitative RT-PCR analysis to assess expression of lineage-specific transcription factors and proteases. Data represents mean of triplicates \pm standard error of the mean. (E) Fluorescence-activated cell sorted $Ik^{-/-}$ c-kit⁺ FcεRI⁺ cells bone marrow cells were Wright-Giemsa stained (original magnification, $\times 100$). Results shown in panels A-B are representative of 4 (blood) and 6 (bone marrow, spleen, and liver) of mice of each genotype. (C-D) Representative of 4 mice. (E) Representative of 3 mice.

with elevated expression of *Cebpa*, and of *Mcpt8*, which encodes a basophil-specific protease.³⁸ Thus, under the influence of IL-3 and SCF, granulated, IgE-responsive mast cells develop with an altered phenotype, including decreased adhesion molecule expression and some features of basophils.

Culture of $Ik^{-/-}$ bone marrow in IL-3 alone results in preferential basophil differentiation

IL-3 alone can support mast cell differentiation, but without SCF, which induces basophil apoptosis,³⁹ IL-3 promotes increased basophil proliferation and survival. To further assess the role of Ikaros in basophil differentiation, wild-type and $Ik^{-/-}$ bone marrow was cultured in IL-3. At day 19 (Figure 3A), as well as at most other time points analyzed (Figure 3B), c-kit⁺ FcεRI⁺ cells comprise a larger proportion of cells in wild-type IL-3 cultures, whereas c-kit⁺ FcεRI⁺ cells are more prevalent in $Ik^{-/-}$ cultures.

To confirm the lineage of IL-3-differentiated $Ik^{-/-}$ cells, we evaluated the expression of basophil markers^{8,40,41} at day 28 (Figures 3C-D). Consistent with a mast cell phenotype, wild-type c-kit⁺ FcεRI⁺ cells are 2B4⁺, IL-3Rα^{lo}, CD11b⁻, and Thy1.2⁻ (Figure 3D, top panel). $Ik^{-/-}$ c-kit⁺ FcεRI⁺ cells show the 2B4⁺, CD11b⁺, Thy1.2⁺, and IL-3Rα^{hi} phenotype characteristic of basophils (Figure 3D, bottom panel). $Ik^{-/-}$ c-kit⁺ FcεRI⁺ cells exhibit an intermediate phenotype with reduced expression of 2B4, CD11b, Thy1.2, and IL-3R compared with wild-type cells (Figure 3D, middle panel). Fluorescence-activated cell sorted $Ik^{-/-}$ c-kit⁺ FcεRI⁺ cells exhibit the hallmark bi-lobed nucleus of basophils (Figure 3E). As in IL-3 and SCF cultures, *Cebpa* expression predominates in $Ik^{-/-}$ IL-3 cultures and there is a corresponding reduction in *Mitf*, *Stat5a*, and *Hes1* expression (Figure 3E). Thus, culture with IL-3 alone in the absence of Ikaros enhances basophil lineage development from bone marrow.

We also investigated the effects of Ikaros deficiency on the kinetics of mast cell and basophil lineage-determining gene expression under IL-3 culture conditions. There is an inducible and steady increase in the expression of *Mitf*, *Stat5*, and *Hes1* in wild-type, but not $Ik^{-/-}$ cultures through week 6 (Figure 2G). Although *Cebpa*

transcript levels are similar at the beginning of culture, expression declines in wild-type cultures correlating with the normal decline of basophil numbers. In contrast, robust induction of *Cebpa* is maintained in $Ik^{-/-}$ cultures over time, correlating with basophil persistence. Expression of *Gata1*, *Gata2*, and *Pul1* is similar in both wild-type and $Ik^{-/-}$ cells at early time points, although some disparities are observed at later times (data not shown). Therefore, Ikaros acts early in response to IL-3 signals to induce expression of mast cell-specifying genes and suppress basophil-specifying genes.

$Ik^{-/-}$ mice exhibit basophilia in the absence of infection


Next, we examined basophils in vivo. There is an increase in the frequency of c-kit⁺ FcεRI⁺ cells in the blood, bone marrow, and spleen (Figure 4A), as well as liver (not shown) of $Ik^{-/-}$ mice relative to wild-type animals. The absolute numbers of basophils are also increased in the bone marrow (Figure 4B) and spleen (not shown), whereas eosinophil numbers are similar. Isolated $Ik^{-/-}$ c-kit⁺ FcεRI⁺ bone marrow cells are 2B4⁺, CD11b⁺, Thy1.2⁺, and IL3Rα^{hi} (Figure 4C), and express *Cebpa*, *Gata2*, and *Mcpt8* transcripts. *Cpa3* is expressed at low levels in these cells, and *Mitf*, *Stat5a*, and *Hes1* transcripts are virtually undetectable (Figure 4D). Staining of sorted cells reveals a segmented granulocytic nucleus (Figure 4E). We conclude that the expanded populations of c-kit⁺ FcεRI⁺ cells in $Ik^{-/-}$ mice are basophils.

Ikaros exerts cell-intrinsic effects on basophil lineage choice in vivo and in vitro

Bone marrow chimeras were generated to assess the potential cell-intrinsic effects of Ikaros on basophil development in vivo. Because mast cells are radiation-resistant, we reasoned that mast cell-deficient *Kit*^{W/W^v mice would be suitable recipients, allowing us to assess restoration of both mast cell and basophil populations.^{42,43} However, $Ik^{-/-}$ -transplanted animals had poor survival beyond 1 month, insufficient time for mast cells to repopulate tissues.}

Basophils were assessed 2 to 4 weeks after bone marrow transfer. Recipients of $Ik^{-/-}$ bone marrow showed increased c-kit⁺ FcεRI⁺

Figure 5. Cell-intrinsic actions of Ikaros drive basophil differentiation. Bone marrow chimeras were generated by transferring either wild-type or *Ik*^{-/-} bone marrow into lethally irradiated *Kit*^{W/W^v recipients. (A) Flow cytometry of c-kit⁺ FcεRI⁺ basophils in indicated tissues at 4 weeks. (B) Percentage c-kit⁺ FcεRI⁺ basophils in the indicated tissues of individual chimeric mice. (C) Basophil lineage marker expression on *Ik*^{-/-} c-kit⁺ FcεRI⁺ bone marrow cells. Representative of 4 animals. (D) Fluorescence-activated cell sorted c-kit⁺ FcεRI⁺ bone marrow cells from *Ik*^{-/-} - *Kit*^{W/W^v chimeras express basophil lineage genes, as determined by quantitative RT-PCR. Representative of 4 mice. n.d., not detected. (E) Genotyping of bone marrow basophils sorted from *Ik*^{-/-} chimeras. Results represent analyses of 2 recipients of *Ik*^{-/-} bone marrow. (F) Bone marrow cells from *Ik*^{+/+} mice were infected with a dominant-negative Ikaros retrovirus (*Ik7*; MSCV-Ik7-IRES-H-2K^k) or control retrovirus (MSCV-IRES-H-2K^k) prior to culture with IL-3 (5 ng/mL) for 2 weeks. Infected (H-2K^k) c-kit⁺ FcεRIα⁺ and c-kit⁻ FcεRIα⁺ cells were identified by flow cytometry and (G) basophil:mast cell ratios calculated. (H) H-2K^k cells from control and dominant-negative infections were isolated using anti-H-2K^k MACS beads and the expression of lineage-associated genes assessed by quantitative RT-PCR. Data are expressed as the mean of 3 separate analyses ± standard deviation using RNA isolated from same bone marrow culture. Each complementary DNA primer set was run in triplicate. **P* < .05; ***P* < .01; ****P* < .001.}}



CD11b⁺ Thy1.2⁺ cells in the bone marrow, spleen (Figures 5A-B), and liver (not shown) relative to wild-type bone marrow recipients, with basophil frequencies comparable to that of naive *Ik*^{-/-} mice (compare Figure 5A-B with Figure 4A-B). These cells are CD11b^{hi} and Thy1.1⁺ (Figure 5C). Sorted c-kit⁺ FcεRI⁺ bone marrow cells express *Cebpa*, *Gata2*, and *Mcpt8*, but not *Mitf*, *Stat5*, or *Hes1* (Figure 5D). Genotyping confirmed that these cells were *Ik*^{-/-} and thus transplant-derived (Figure 5E).

To further validate the cell-intrinsic actions of Ikaros, wild-type bone marrow was infected with MSCV-Ik7-IRES-H2K^k, a retrovirus that expresses a dominant-negative Ik isoform (*Ik7*) or control MSCV-IRES-H2K^k.⁴⁴ After culture for 2 weeks with IL-3, c-kit⁺ FcεRIα⁺, and c-kit⁻ FcεRIα⁺ cells were identified within the infected (H-2K^k) populations. The proportion of c-kit⁺ FcεRIα⁺ cells is substantially higher in *Ik7*-transduced cultures than in cultures infected with control virus (Figure 5F). Purified H-2K^k, *Ik7*-transduced cells show reduced expression of *Mitf*, *Hes1*, and *Tpsb2* (*Mcpt6*), and increased *Cebpa* and *Mcpt8* expression compared with control cells (Figure 5G). We examined the phenotype of uninfected (H-2K^k) cells in control- and *Ik7*-infected cultures (supplemental Figure 2) and saw no difference in the mast cell to

basophil ratios. Together, these findings support the idea that Ikaros acts intrinsically in response to IL-3 signaling to suppress basophil differentiation.

BaPs are increased in *Ik*^{-/-} mice

To determine if basophil expansion was a result of earlier Ikaros-driven changes in precursors, we compared the distribution of basophil-associated myeloid progenitors in the bone marrow and spleen of wild-type and *Ik*^{-/-} mice. As previously reported,^{45,46} *Ik*^{-/-} bone marrow has reduced numbers of lymphocytes, whereas in the spleen, total numbers are similar to that of wild-type mice (Figure 6A). The Lin⁻ Sca-1⁺ c-kit⁺, but not the Lin⁻ Sca-1⁻ c-kit⁺ compartment in the bone marrow is expanded in *Ik*^{-/-} mice. Within the Lin⁻ Sca-1⁺ c-kit⁺ compartment, there is a complete loss of CD34⁺ CD135⁺ lymphomyeloid primed progenitors, whereas within the Lin⁻ Sca-1⁻ c-kit⁺ compartment, CD34⁺ CD16/32⁺ granulocyte-monocyte progenitors are reduced (supplemental Figure 3).

Next, we examined direct precursors of mast cells and basophils. Although Lin⁻ c-kit⁺ CD34⁺ FcεRIα⁻ CD27⁻ ST2L⁺ MCP¹⁶ are present in similar proportions, Lin⁻ CD34⁺ c-kit⁻ FcεRIα⁺ BaP




Figure 6. Direct progenitors of basophils express Ik and are increased in *Ik*^{-/-} mice. Bone marrow and spleen leukocytes were isolated from *Ik*^{+/+} (*+/+*) and *Ik*^{-/-} (*-/-*) mice. (A) Total leukocytes in bone marrow (bilateral femoral/tibial) and spleen of *+/+* and *-/-* animals. Mean ± standard error of the mean (SEM) (n = 10 for *+/+*, n = 11 for *-/-*). (B) Representative plots of Lin⁻ CD34⁺ FcεR1a⁺ c-kit⁺ BaPs and Lin⁻ Sca-1⁻ c-kit⁺ CD27⁻ ST2L⁺ β7 integrin⁺ mast cell progenitors in bone marrow and the spleen and Lin⁻ c-kit⁺ CD16/32⁺ β7 integrin^{hi} BMCP in the spleen of *Ik*^{+/+} and *Ik*^{-/-} mice. Numbers represent percentage of parent gate indicated below plots. (C) Quantification of frequencies of indicated cell types as a percentage of total SYTOX⁻ (live) cells in flow sample. Bone marrow and spleen BaP (n = 5 for *+/+* and *-/-*); bone marrow and spleen MCp (n = 5 for *+/+* and n = 6 for *-/-*); BMCP (n = 10 for *+/+* and 11 for *-/-*). (D) Estimated mean absolute cell numbers per organ and 95% confidence interval of mean for indicated cell types, derived from means and SEM of frequency and total cell data in panels A,C. Independence was assumed and SEM were combined by the formula: $SEM_{1,2} = \sqrt{\mu_1^2 SEM_1^2 + \mu_2^2 SEM_2^2 + SEM_1^2 SEM_2^2}$. (E) Expression of *Ikzf1* (all *Ik* isoforms) in indicated cell populations assessed by quantitative RT-PCR. CD4⁺ T cells were isolated from naive mice. In vitro bone marrow (BM)-derived basophil cells are isolated from 9-day cultures and mast cells, from 6-week cultures with IL-3 alone. GMPs, BaPs were sorted from bone marrow while purified BMCPs were isolated from spleen. Ex vivo-elicited basophils were derived from the bone marrow and livers of mice after treatment with IL-3 complexes (n = 1 for ex vivo IL-3-elicited complex basophils; n = 3 for other samples). **P* < .05; ***P* < .01.

and splenic Lin⁻ c-kit⁺ CD34⁺ CD16/32⁺ β7^{hi} BMCP¹ are expanded as a proportion of all cells analyzed, with BaP increased approximately 10-fold. Similarly, BMCP formed a larger proportion of total cells in *Ik*^{-/-} spleen (Figures 6B-C). Calculated absolute cell numbers recapitulated the changes seen in proportional analyses (Figure 6D).

We observed a population of β7^{mid-lo} cells in the Lin⁻ c-kit⁺ gate in *Ik*^{-/-} spleens that is not present in *Ik*^{+/+} mice. Thus, we measured levels of other splenic myeloid progenitors and observed increases in progenitors normally restricted to bone marrow, including GMP, BaP, and MCp (supplemental Figure 4). The absolute numbers of these cells were also increased (supplemental Table 2). We conclude that basophilia in *Ik*^{-/-} mice is a consequence of expansion of direct progenitors, and that splenic myelopoiesis may also supply basophils in these animals.

The preferential expansion of basophils in *Ik*-deficient mice indicates that *Ik* normally suppresses basophil development. Thus it was predicted that *Ik* expression is extinguished during normal basophil differentiation. To assess this possibility, we measured *Ikzf1*


transcript levels in wild type cells by quantitative RT-PCR using primers complementary to sequences within exons 1 and 7. Surprisingly, *Ik* transcripts were detected in sorted IL-3-cultured bone marrow basophils, in basophils isolated directly from IL-3 complex-stimulated mice, and in sorted GMP, BMCP, and BaP (Figure 6E). The relative levels of expression were similar to those in mast cells and naive T cells. Thus, normal basophil differentiation is not associated with a downregulation or complete loss of *Ikzf1* gene expression.

Ikros binds directly to *Cebpa* and *Hes1*, and loss of *Ik* alters H3K4me3 status

Loss of *Ik* activity results in altered expression of multiple genes that contribute to mast cell-basophil lineage choice and function. Reciprocal expression of *Hes1* and *Cebpa* is particularly notable, as *Hes1*, a notch target, which is necessary for mast cell development and directly inhibits *Cebpa* expression.⁴⁷ Similar cross-repression between C/EBP-α and MITF, another critical mast

Figure 7. Ikaros binds to the *Cebpa* and *Hes1* genes, and loss of *Ik* results in altered histone modifications.

(A) RVista/MultiTF analysis of consensus *Ikzf1* (*Ik*), *Stat5a*- and *Gata*-binding sites (tick marks) in the flanking regions (transcriptional start site and 3' CNS regions [II-IV]) of the *Cebpa* gene and upstream region of the *Hes1* gene (promoter [*Hes1p*]). BLUE peaks and boxes denote exons and YELLOW, PINK and RED peaks designate intergenic or flanking regions exhibiting interspecies homology. (B) ChIP assays detect Ikaros-binding to the *Cebpa* and *Hes1* genes in wild-type bone marrow derived mast cells. Primers flanking indicated regions (green boxes) were used. Data are expressed as percent of total input DNA. Negative controls (n.c.) include quantitative RT-PCR amplification with primers for a sequence distant from any known Ikaros-binding site. (C) H3K4me3 histone modifications at consensus Ikaros-binding sites, assessed by ChIP. Data are expressed as percent of total input DNA after subtraction of IgG control values. Results shown in panels B-C are representative of 4 experiments using 2 independent bone marrow cultures derived from wild-type and *Ik*^{-/-} mice.



cell factor, has recently been demonstrated.⁴⁸ RVista/MultiTF analyses revealed that both *Hes1* and *Cebpa* have multiple consensus Ikaros-binding sites that are often clustered with consensus STAT and GATA sites, as previously observed within the *Ii4* locus⁴⁹ (Figure 7A), while *Mitf* lacked these clusters (data not shown). ChIP assays were performed with wild-type bone marrow-derived mast cells after 4 weeks of IL-3 culture to evaluate Ikaros-binding at clustered sites. Ikaros associates with multiple regions flanking the *Cebpa* coding region as well as the *Hes1* promoter region (Figure 7B). These regions were assessed for H3K4 trimethylation (H3K4me3), a stable chromatin modification most often associated with poised or actively transcribed chromatin^{50,51} in week 4 wild-type and *Ik*^{-/-} cultures. Wild-type cells exhibit decreased H3K4me3 at the *Cebpa* locus and increased H3K4me3 at the *Hes1* promoter when compared with *Ik*^{-/-} cells (Figure 7C).

Discussion

These studies establish a critical and cell-intrinsic role for Ikaros in basophil development in vitro and in vivo, although we cannot exclude the possibility that Ikaros also has extrinsic influences. Ikaros affects the expression of multiple lineage-specifying genes, including *Cebpa*,^{1,48} *Mitf*,^{4,48} and *Hes1*.⁴⁷ At least two of these, *Cebpa*, required for basophil differentiation, and *Hes1*, a mast-cell specifying factor,⁴⁷ appear to be direct targets of Ikaros in differentiated cells as Ikaros-binding is detected at regulatory sequences within these gene loci. In IL-3-differentiated *Ik*^{-/-} cells, changes in H3K4me3 modifications are observed at these loci as well, reflecting aberrant increased (*Cebpa*) or decreased (*Hes1*) gene expression. In view of the central role that C/EBP- α plays in basophil development, loss of Ikaros-mediated suppression of *Cebpa* coupled with decreased expression of *Hes1* and *Mitf* in BaPs provides a molecular explanation for basophil expansion in *Ik*^{-/-} mice.

It is still unclear where Ikaros acts during the transition from a multipotent precursor to a committed basophil. In addition to previously reported increases in GMPs,⁴⁵ we observe dramatic increases in the proportion and total numbers of BaPs and BMCPs in both the bone marrow and the spleen. However, there does not appear to be a corresponding net reduction in MCPs when total numbers in the bone marrow and spleen are considered together. Thus, we speculate that the loss of Ikaros results in preferential GMP to BaP differentiation, a possibility we intend to investigate in the future.

Our data does not support a role for Ikaros in mast cell-basophil lineage choice in vivo. Despite profound alterations in mast cell development in vitro, there are no overall deficits in MCPs, and only intestinal mast cell populations are reduced in *Ik*^{-/-} mice. Therefore, basophil expansion does not occur at the expense of mast cell development, and Ikaros-independent pathways of mast cell differentiation must exist. Although Ikaros can affect mast cell differentiation in vitro, the major effects are observed in cultures with IL-3 and no SCF. The addition of SCF, which drives basal mast cell differentiation, can induce mast cell development in vitro in the absence of Ikaros, albeit with an altered phenotype, suggesting that SCF/c-kit signals may be partially Ikaros-independent.

If mast cell development is relatively normal in *Ik*^{-/-} mice, how can the selective loss of intestinal mast cells and MCP in *Ik*^{-/-} mice be explained? The pronounced reduction in the expression of CD49d, the $\alpha 4$ integrin subunit that pairs with $\beta 7$, may provide a clue. The $\alpha 4\beta 7$ integrin is required for directing mast cell precursors to the gut,³³ and we speculate that deficits in $\alpha 4\beta 7$ expression result in impaired homing of MCPs in *Ik*^{-/-} mice, and thus reduced intestinal mast cell numbers. It remains to be determined whether Ikaros affects mast cell function. Unfortunately, the lack of most lymphoid cells and early mortality of *Ik*^{-/-} mice preclude in vivo assessment of mast cell function in most disease models.

Ikaros regulates fate decisions in several multipotent precursor cells, including naive CD4⁺ T cells.^{24,49,52} Still, how Ikaros integrates the unique differentiation signals that yield these distinct effector cells

is unknown. Basophil differentiation and expansion can normally occur in infection settings where high levels of IL-3 are produced by CD4⁺ T cells.⁵³⁻⁵⁵ We initially considered a model in which Ikaros expression is extinguished in BaPs in response to IL-3 or other basophil-inducing signals leading to de-repression of *Cebpa* and repression of *Hes1* and *Mitf*. However, basophils and their precursors express Ikaros messenger RNA at levels similar to mast cells and T cells, indicating an alternative hypothesis. That is, Ikaros function is altered through post-translational modifications or alternate isoform usage in response to differentiation signals, such as IL-3. There is evidence to support this contention. Ikaros comprises a family of dimerizing isoforms, which can differ in DNA-binding capacity.^{56,57} Interaction of non-DNA-binding isoforms with DNA-binding isoforms has been shown to prevent the association of Ikaros with target genes,⁴⁴ indicating that selective isoform expression can modulate Ikaros function. DNA-binding isoforms undergo changes as a result of RNA splicing as lymphoid lineage commitment proceeds.⁵⁸ Similarly, a decrease in the expression of Ik1 and Ik2 isoforms is observed in activated Th1, but not Th2 cells.⁵⁹ Within the myeloid lineage, early myeloid/neutrophil precursors have unique patterns of isoform expression,^{58,60,61} and expression of dominant-negative Ikaros isoforms is often observed in some leukemia subtypes.⁶²

In summary, our results show that Ikaros restricts basophil expansion under steady-state conditions. Basophils are normally scarce, comprising less than 0.5% of total leukocytes in blood, bone marrow, and the spleen.² We propose that in the steady state, where basal levels of SCF and IL-3 are present, Ikaros activity is sustained, promoting expression of *Mitf* and *Hes1* and repression of *Cebpa* in progenitor populations. Subsequently, *Hes1* and *MITF* may directly contribute to *Cebpa* repression. When IL-3 is abundant, basophil differentiation is favored due to a reduction of Ikaros activity, perhaps via altered isoform expression, releasing *Cebpa* suppression. Given the profound influence that basophils exert on inflammation in

allergic disease, autoimmunity, cancer, and infection, our data provide strong rationale for future studies aimed at more detailed dissection of the mechanisms underlying the control of the development of these cells by Ikaros.

Acknowledgments

The authors thank Dr Susan Winandy, Boston University, for the Ik^{-/-} mice.

This work was supported by funding from the Northwestern University Flow Cytometry Facility and by a grant from the National Institutes of Health National Cancer Institute Cancer Center Support (P30CA060553, R21AI88299) (M.A.B.), (NRS F30ES017378) (C.S.), and an American Heart Association postdoctoral fellowship to K.N.R.

Authorship

Contributions: K.N.R., C.S., and G.D.G. designed and performed experiments, analyzed results, and made figures; K.N.R., C.S., and M.A.B. designed the research and wrote the manuscript; and B.M. prepared and provided essential experimental samples.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Melissa Ann Brown, Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, 303 E Chicago Ave, Tarry 6-701, Chicago, IL 60611; e-mail: m-brown12@northwestern.edu.

References

- Arinobu Y, Iwasaki H, Gurish MF, et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. *Proc Natl Acad Sci USA*. 2005;102(50):18105-18110.
- Karasuyama H, Obata K, Wada T, Tsujimura Y, Mukai K. Newly appreciated roles for basophils in allergy and protective immunity. *Allergy*. 2011; 66(9):1133-1141.
- Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health and disease. *Ann N Y Acad Sci*. 2008;1143:83-104.
- Kim DK, Morii E, Ogihara H, et al. Different effect of various mutant *MITF* encoded by *mi*, *Mior*, or *Miwh* allele on phenotype of murine mast cells. *Blood*. 1999;93(12):4179-4186.
- Min B. Basophils: what they 'can do' versus what they 'actually do'. *Nat Immunol*. 2008;9(12): 1333-1339.
- Min B, Paul WE. Basophils and type 2 immunity. *Curr Opin Hematol*. 2008;15(1):59-63.
- Siracusa MC, Perrigoue JG, Comeau MR, Artis D. New paradigms in basophil development, regulation and function. *Immunol Cell Biol*. 2010; 88(3):275-284.
- Ohmori K, Luo Y, Jia Y, et al. IL-3 induces basophil expansion in vivo by directing granulocyte-monocyte progenitors to differentiate into basophil lineage-restricted progenitors in the bone marrow and by increasing the number of basophil/mast cell progenitors in the spleen. *J Immunol*. 2009;182(5):2835-2841.
- Siracusa MC, Saenz SA, Hill DA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. *Nature*. 2011;477(7363):229-233.
- Voehringer D. Basophils in allergic immune responses. *Curr Opin Immunol*. 2011;23(6): 789-793.
- Tsujimura Y, Obata K, Mukai K, et al. Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. *Immunity*. 2008;28(4):581-589.
- Sokol CL, Medzhitov R. Emerging functions of basophils in protective and allergic immune responses. *Mucosal Immunol*. 2010;3(2):129-137.
- van Panhuys N, Prout M, Forbes E, Min B, Paul WE, Le Gros G. Basophils are the major producers of IL-4 during primary helminth infection. *J Immunol*. 2011;186(5):2719-2728.
- Arinobu Y, Iwasaki H, Akashi K. Origin of basophils and mast cells. *Allergol Int*. 2009;58(1): 21-28.
- Hallgren J, Gurish MF. Pathways of murine mast cell development and trafficking: tracking the roots and routes of the mast cell. *Immunol Rev*. 2007; 217:8-18.
- Chen CC, Grimbaldston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. *Proc Natl Acad Sci USA*. 2005; 102(32):11408-11413.
- Franco CB, Chen CC, Drukker M, Weissman IL, Galli SJ. Distinguishing mast cell and granulocyte differentiation at the single-cell level. *Cell Stem Cell*. 2010;6(4):361-368.
- Kitamura Y, Oboki K, Ito A. Molecular mechanisms of mast cell development. *Immunol Allergy Clin North Am*. 2006;26(3):387-405.
- Shelburne CP, McCoy ME, Piekorz R, et al. Stat5 expression is critical for mast cell development and survival. *Blood*. 2003;102(4):1290-1297.
- Tshori S, Nechushtan H. Mast cell transcription factors—regulators of cell fate and phenotype. *Biochim Biophys Acta*. 2012;1822(1):42-48.
- Yoshida T, Ng SY, Georgopoulos K. Awakening lineage potential by Ikaros-mediated transcriptional priming. *Curr Opin Immunol*. 2010; 22(2):154-160.
- Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and Ikaros. *Nat Rev Immunol*. 2002;2(3):162-174.
- John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. *Mol Immunol*. 2011;48(9-10): 1272-1278.
- Ng SY, Yoshida T, Georgopoulos K. Ikaros and chromatin regulation in early hematopoiesis. *Curr Opin Immunol*. 2007;19(2):116-122.
- Ng SY, Yoshida T, Zhang J, Georgopoulos K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. *Immunity*. 2009;30(4):493-507.
- Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. *Cell*. 1994;79(1):143-156.

27. Wang JH, Nichogiannopoulou A, Wu L, et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. *Immunity*. 1996;5(6):537-549.
28. Wu L, Nichogiannopoulou A, Shortman K, Georgopoulos K. Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. *Immunity*. 1997;7(4):483-492.
29. Dijon M, Bardin F, Murati A, Batoz M, Chabannon C, Tonnelle C. The role of Ikaros in human erythroid differentiation. *Blood*. 2008;111(3):1138-1146.
30. Dumortier A, Kirstetter P, Kastner P, Chan S. Ikaros regulates neutrophil differentiation. *Blood*. 2003;101(6):2219-2226.
31. Gregory GD, Raju SS, Winandy S, Brown MA. Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE. *J Clin Invest*. 2006;116(5):1327-1336.
32. Blank U, Rivera J. Assays for regulated exocytosis of mast cell granules. *Curr Protoc Cell Biol*. 2006;Chapter 15:Unit 15.11.
33. Gurish MF, Tao H, Abonia JP, et al. Intestinal mast cell progenitors require CD49beta7 (alpha4beta7 integrin) for tissue-specific homing. *J Exp Med*. 2001;194(9):1243-1252.
34. Kathrein KL, Lorenz R, Innes AM, Griffiths E, Winandy S. Ikaros induces quiescence and T-cell differentiation in a leukemia cell line. *Mol Cell Biol*. 2005;25(5):1645-1654.
35. Oh K, Shen T, Le Gros G, Min B. Induction of Th2 type immunity in a mouse system reveals a novel immunoregulatory role of basophils. *Blood*. 2007;109(7):2921-2927.
36. Tsai M, Shih LS, Newlands GF, et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. *J Exp Med*. 1991;174(1):125-131.
37. Feyerabend TB, Hausser H, Tietz A, et al. Loss of histochemical identity in mast cells lacking carboxypeptidase A. *Mol Cell Biol*. 2005;25(14):6199-6210.
38. Ugajin T, Kojima T, Mukai K, et al. Basophils preferentially express mouse Mast Cell Protease 11 among the mast cell tryptase family in contrast to mast cells. *J Leukoc Biol*. 2009;86(6):1417-1425.
39. Dvorak AM, Seder RA, Paul WE, Morgan ES, Galli SJ. Effects of interleukin-3 with or without the c-kit ligand, stem cell factor, on the survival and cytoplasmic granule formation of mouse basophils and mast cells in vitro. *Am J Pathol*. 1994;144(1):160-170.
40. Mukai K, Matsuoka K, Taya C, et al. Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. *Immunity*. 2005;23(2):191-202.
41. Valent P, Sillaber C, Bettelheim P. The growth and differentiation of mast cells. *Prog Growth Factor Res*. 1991;3(1):27-41.
42. Laky K, Lefrançois L, Puddington L. Age-dependent intestinal lymphoproliferative disorder due to stem cell factor receptor deficiency: parameters in small and large intestine. *J Immunol*. 1997;158(3):1417-1427.
43. Kobayashi T, Nakano T, Nakahata T, et al. Formation of mast cell colonies in methylcellulose by mouse peritoneal cells and differentiation of these cloned cells in both the skin and the gastric mucosa of W/Wv mice: evidence that a common precursor can give rise to both "connective tissue-type" and "mucosal" mast cells. *J Immunol*. 1986;136(4):1378-1384.
44. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. *Cell*. 1995;83(2):289-299.
45. Nichogiannopoulou A, Trevisan M, Neben S, Friedrich C, Georgopoulos K. Defects in hemopoietic stem cell activity in Ikaros mutant mice. *J Exp Med*. 1999;190(9):1201-1214.
46. Yoshida T, Ng SY-M, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. *Nat Immunol*. 2006;7(4):382-391.
47. Sakata-Yanagimoto M, Nakagami-Yamaguchi E, Saito T, et al. Coordinated regulation of transcription factors through Notch2 is an important mediator of mast cell fate. *Proc Natl Acad Sci USA*. 2008;105(22):7839-7844.
48. Qi X, Hong J, Chaves L, et al. Antagonistic Regulation by the Transcription Factors C/EBP α and MITF Specifies Basophil and Mast Cell Fates. *Immunity*. 2013;39(1):97-110.
49. Quirion MR, Gregory GD, Umetsu SE, Winandy S, Brown MA. Cutting edge: Ikaros is a regulator of Th2 cell differentiation. *J Immunol*. 2009;182(2):741-745.
50. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. *Mol Cell*. 2007;25(1):15-30.
51. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. *Cell*. 2007;130(1):77-88.
52. Umetsu SE, Winandy S. Ikaros is a regulator of IL10 expression in CD4+ T cells. *J Immunol*. 2009;183(9):5518-5525.
53. Lantz CS, Boesiger J, Song CH, et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. *Nature*. 1998;392(6671):90-93.
54. Lantz CS, Min B, Tsai M, Chatterjea D, Dranoff G, Galli SJ. IL-3 is required for increases in blood basophils in nematode infection in mice and can enhance IgE-dependent IL-4 production by basophils in vitro. *Lab Invest*. 2008;88(11):1134-1142.
55. Ohnmacht C, Voehringer D. Basophil effector function and homeostasis during helminth infection. *Blood*. 2009;113(12):2816-2825.
56. Molnár A, Wu P, Largespada DA, et al. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. *J Immunol*. 1996;156(2):585-592.
57. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. *EMBO J*. 1996;15(19):5358-5369.
58. Klug CA, Morrison SJ, Masek M, Hahn K, Smale ST, Weissman IL. Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes. *Proc Natl Acad Sci USA*. 1998;95(2):657-662.
59. Thomas RM, Chen C, Chunder N, et al. Ikaros silences T-bet expression and interferon-gamma production during T helper 2 differentiation. *J Biol Chem*. 2010;285(4):2545-2553.
60. Payne KJ, Huang G, Sahakian E, et al. Ikaros isoform x is selectively expressed in myeloid differentiation. *J Immunol*. 2003;170(6):3091-3098.
61. Payne KJ, Nicolas JH, Zhu JY, Barsky LW, Crooks GM. Cutting edge: predominant expression of a novel Ikaros isoform in normal human hemopoiesis. *J Immunol*. 2001;167(4):1867-1870.
62. Yagi T, Hibi S, Takanashi M, et al. High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis. *Blood*. 2002;99(4):1350-1355.